SIBN Stock Analysis: Si-Bone | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 818m USD | 12M Return: 14% | US8257041090 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 8.86M
Qual. Beats: 6
Rev. Trend: 99.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 7.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
SI-BONE, Inc. (NASDAQ: SIBN) is a medical device company that develops procedural solutions for compromised bone, with a focus on titanium implants used in sacroiliac (SI) joint and pelvic fixation procedures. Founded in 2008 and headquartered in Santa Clara, California, the company went public in October 2018 and operates within the broader orthopedic medical device sector. Its product line centers on the iFuse franchise, which includes several procedurally distinct implants (such as iFuse 3D, iFuse Torq, and iFuse Bedrock Granite) designed to stabilize the SI joint and support spinal fusion constructs.
The company primarily relies on a direct sales force complemented by third-party sales agents and resellers to reach its clinical customers, which are typically orthopedic and spinal surgeons. SI-BONEs business model reflects a niche-focused approach common in the orthopedic device industry, where specialized procedural solutions are sold to a concentrated base of physicians and hospitals rather than through broad consumer channels. The sacroiliac joint fusion market remains an emerging segment within orthopedics, with adoption historically constrained by underdiagnosis of SI joint dysfunction as a source of low back pain.
- iFuse procedure volume growth drives sustained revenue acceleration
- Medicare reimbursement policy remains critical tailwind for SI joint fusion adoption
- Competition from alternative SI joint fusion devices pressures market share
| Net Income: -14.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 6.61 > 1.0 |
| NWC/Revenue: 91.70% < 20% (prev 98.62%; Δ -6.92% < -1%) |
| CFO/TA 0.01 > 3% & CFO 1.87m > Net Income -14.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 9.15 > 1.5 & < 3 |
| Outstanding Shares: last quarter (44.2m) vs 12m ago 3.35% < -2% |
| Gross Margin: 79.53% > 18% (prev 79.45%; Δ 0.08% > 0.5%) |
| Asset Turnover: 89.06% > 50% (prev 80.23%; Δ 8.83% > 0%) |
| Interest Coverage Ratio: -3.67 > 6 (EBIT TTM -13.5m / Interest Expense TTM 3.67m) |
| A: 0.79 (Total Current Assets 219.9m - Total Current Liabilities 24.0m) / Total Assets 248.8m |
| B: -1.84 (Retained Earnings -458.7m / Total Assets 248.8m) |
| C: -0.06 (EBIT TTM -13.5m / Avg Total Assets 239.8m) |
| D: 2.75 (Book Value of Equity 182.3m / Total Liabilities 66.4m) |
| Altman-Z'' = 1.66 = BB |
| DSRI: 1.11 (Receivables 31.2m/24.4m, Revenue 213.6m/185.3m) |
| GMI: 1.00 (GM 79.45% / 79.53%) |
| AQI: 0.66 (AQ_t 0.00 / AQ_t-1 0.00) |
| SGI: 1.15 (Revenue 213.6m / 185.3m) |
| TATA: -0.07 (NI -14.6m - CFO 1.87m) / TA 248.8m) |
| Beneish M = -3.04 (Cap -4..+1) = AA |
As of August 08, 2026, the stock is trading at USD 18.61 with a total of 297,276 shares traded. Over the past week, the price has changed by +4.79%, over one month by +7.57%, over three months by +43.71% and over the past year by +14.03%.
Current recommended Stop Loss: 17.30 (which is 7% or 1.6 ATR below the current price).
Si-Bone has received a consensus analysts rating of 4.56. Therefore, it is recommended to buy SIBN.
- StrongBuy: 5
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 24.4 | 31.3% |
P/S = 3.8286
P/B = 4.4017
Revenue TTM = 213.6m USD
EBIT TTM = -13.5m USD
EBITDA TTM = -8.29m USD
Long Term Debt = 35.6m USD (from longTermDebt, last fiscal year)
Short Term Debt = 426k USD (from shortTermDebt, last quarter)
Debt = 43.3m USD (corrected: LT Debt 35.6m + ST Debt 426k) + Leases 7.35m
Net Debt = -102.6m USD (calculated: Debt 43.3m - CCE 145.9m)
Enterprise Value = 715.2m USD (817.8m + Debt 43.3m - CCE 145.9m)
Interest Coverage Ratio = -3.67 (Ebit TTM -13.5m / Interest Expense TTM 3.67m)
EV/FCF = 80.13x (Enterprise Value 715.2m / FCF TTM 8.93m)
FCF Yield = 1.25% (FCF TTM 8.93m / Enterprise Value 715.2m)
FCF Margin = 4.18% (FCF TTM 8.93m / Revenue TTM 213.6m)
Net Margin = -6.85% (Net Income TTM -14.6m / Revenue TTM 213.6m)
Gross Margin = 79.53% ((Revenue TTM 213.6m - Cost of Revenue TTM 43.7m) / Revenue TTM)
Gross Margin QoQ = 79.54% (prev 79.76%)
Tobins Q-Ratio = 2.88 (Enterprise Value 715.2m / Total Assets 248.8m)
Interest Expense / Debt = 8.47% (Interest Expense 3.67m / Debt 43.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -10.6m (EBIT -13.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.75 (Total Current Assets 219.9m / Total Current Liabilities 32.6m)
Debt / Equity = 0.24 (Debt 43.3m / totalStockholderEquity, last quarter 182.3m)
Debt / EBITDA = 12.37 (negative EBITDA) (Net Debt -102.6m / EBITDA -8.29m)
Debt / FCF = -11.50 (Net Debt -102.6m / FCF TTM 8.93m)
Total Stockholder Equity = 177.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -6.10% (Net Income -14.6m / Total Assets 248.8m)
RoE = -8.23% (Net Income TTM -14.6m / Total Stockholder Equity 177.7m)
RoCE = -6.31% (EBIT -13.5m / Capital Employed (Equity 177.7m + L.T.Debt 35.6m))
RoIC = -4.96% (negative operating profit) (NOPAT -10.6m / Invested Capital 214.5m)
WACC = 9.04% (E(817.8m)/V(861.1m) * Re(9.16%) + D(43.3m)/V(861.1m) * Rd(8.47%) * (1-Tc(0.21)))
Discount Rate = 9.16% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 99.92 | Cagr: 3.49%
[DCF] Terminal Value 73.06% ; FCFF base≈8.93m ; Y1≈8.96m ; Y5≈9.49m
[DCF] Fair Price = 5.29 (EV 132.2m - Net Debt -102.6m = Equity 234.8m / Shares 44.3m; r=9.04% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 2.51 | # QB: 6
Revenue Correlation: 99.71 | Revenue CAGR: 19.92% | SUE: 0.66 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.12 | Chg30d=+4.85% | Revisions=-57% | Analysts=8
EPS current Year (2026-12-31): EPS=-0.42 | Chg30d=+1.19% | Revisions=+62% | GrowthEPS=+3.8% | GrowthRev=+15.4%
EPS next Year (2027-12-31): EPS=-0.34 | Chg30d=+2.64% | Revisions=+29% | GrowthEPS=+18.9% | GrowthRev=+15.5%
[Analyst] Revisions Ratio: +19% (up=8, down=5)